EP3997086C0 - Composés de tétrahydroisoquinoline - Google Patents

Composés de tétrahydroisoquinoline

Info

Publication number: EP3997086C0
Authority: EP; European Patent Office
Prior art keywords: tetrahydroisoquinoline compounds; tetrahydroisoquinoline; compounds
Prior art date: 2019-07-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

EP20740271.0A

Other languages

German (de)

English (en)

Other versions

EP3997086B1 (fr

EP3997086A1 (fr

Inventor

García Miguel Vega

Muelas Pedro Campos

Romero Esther Carrasco

Pérez Asunción Burguete

Gutiérrez Patricia Gómez

González Juan Jesús Pérez

Peypoch Ángel Messeguer

Sánchez Balbino José Alarcón

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

ALLINKY BIOPHARMA

Original Assignee

ALLINKY BIOPHARMA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-07-09

Filing date

2020-07-09

Publication date

2024-06-05

2020-07-09 Application filed by ALLINKY BIOPHARMA filed Critical ALLINKY BIOPHARMA

2022-05-18 Publication of EP3997086A1 publication Critical patent/EP3997086A1/fr

2024-06-05 Application granted granted Critical

2024-06-05 Publication of EP3997086B1 publication Critical patent/EP3997086B1/fr

2024-06-05 Publication of EP3997086C0 publication Critical patent/EP3997086C0/fr

Status Active legal-status Critical Current

2040-07-09 Anticipated expiration legal-status Critical

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

EP20740271.0A 2019-07-09 2020-07-09 Composés de tétrahydroisoquinoline Active EP3997086B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP19382584.1A EP3763711A1 (fr)	2019-07-09	2019-07-09	Composés de tétrahydroisoquinoline
PCT/EP2020/069403 WO2021005165A1 (fr)	2019-07-09	2020-07-09	Composés de tétrahydroisoquinoléine

Publications (3)

Publication Number	Publication Date
EP3997086A1 EP3997086A1 (fr)	2022-05-18
EP3997086B1 EP3997086B1 (fr)	2024-06-05
EP3997086C0 true EP3997086C0 (fr)	2024-06-05

Family

ID=67480113

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP19382584.1A Withdrawn EP3763711A1 (fr)	2019-07-09	2019-07-09	Composés de tétrahydroisoquinoline
EP20740271.0A Active EP3997086B1 (fr)	2019-07-09	2020-07-09	Composés de tétrahydroisoquinoline

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP19382584.1A Withdrawn EP3763711A1 (fr)	2019-07-09	2019-07-09	Composés de tétrahydroisoquinoline

Country Status (6)

Country	Link
US (1)	US20220380357A1 (fr)
EP (2)	EP3763711A1 (fr)
JP (1)	JP2022540580A (fr)
KR (1)	KR20220034181A (fr)
ES (1)	ES2994099T3 (fr)
WO (1)	WO2021005165A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN117677398A (zh)	2021-07-27	2024-03-08	东丽株式会社	用于癌的治疗和/或预防的药品
EP4174241A1 (fr)	2021-11-01	2023-05-03	Memis Oguzhan	Système de construction en bois
CN118922418A (zh) *	2022-03-09	2024-11-08	思路迪生物医药(上海)有限公司	一类作为泛-kras抑制剂的四氢异喹啉类衍生物及其制备方法和应用
CN114874201B (zh) *	2022-04-08	2023-01-20	思路迪生物医药(上海)有限公司	一类泛-kras抑制剂及其制备和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3905982A (en) *	1973-07-23	1975-09-16	Searle & Co	1-Aryl-n-dialkylaminoalkyl-3,4-dihydro-2(1H)-isoquinolinecarboxamides and related compounds
US20120101106A1 (en)	2009-07-09	2012-04-26	Mercer Swati P	Tetrahydronapthyridine Orexin Receptor Antagonists
WO2016033105A1 (fr) *	2014-08-29	2016-03-03	The Board Of Regents Of The University Of Texas System	Nouveaux analogues de la capsazépine pour le traitement du cancer et d'autres maladies prolifératives
RU2020126188A (ru) *	2018-01-10	2022-02-10	Альинки Байофарма	Соединения тетрагидроизохинолина

2019
- 2019-07-09 EP EP19382584.1A patent/EP3763711A1/fr not_active Withdrawn
2020
- 2020-07-09 KR KR1020227004283A patent/KR20220034181A/ko not_active Withdrawn
- 2020-07-09 JP JP2022500647A patent/JP2022540580A/ja active Pending
- 2020-07-09 ES ES20740271T patent/ES2994099T3/es active Active
- 2020-07-09 US US17/625,685 patent/US20220380357A1/en not_active Abandoned
- 2020-07-09 WO PCT/EP2020/069403 patent/WO2021005165A1/fr not_active Ceased
- 2020-07-09 EP EP20740271.0A patent/EP3997086B1/fr active Active

Also Published As

Publication number	Publication date
ES2994099T3 (en)	2025-01-17
WO2021005165A1 (fr)	2021-01-14
JP2022540580A (ja)	2022-09-16
EP3997086B1 (fr)	2024-06-05
US20220380357A1 (en)	2022-12-01
EP3763711A1 (fr)	2021-01-13
EP3997086A1 (fr)	2022-05-18
KR20220034181A (ko)	2022-03-17

Legal Events

Date	Code	Title	Description
2020-07-24	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: UNKNOWN
2021-01-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2022-04-15	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2022-04-15	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2022-05-18	17P	Request for examination filed	Effective date: 20220202
2022-05-18	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2022-10-19	DAV	Request for validation of the european patent (deleted)
2022-10-19	DAX	Request for extension of the european patent (deleted)
2023-02-27	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2023-02-27	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2023-03-29	INTG	Intention to grant announced	Effective date: 20230228
2023-06-07	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2023-06-10	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2023-06-10	GRAL	Information related to payment of fee for publishing/printing deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR3
2023-06-10	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2023-07-07	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2023-07-19	INTC	Intention to grant announced (deleted)
2023-08-09	17Q	First examination report despatched	Effective date: 20230706
2024-01-01	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2024-01-01	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2024-01-24	INTG	Intention to grant announced	Effective date: 20240102
2024-05-03	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2024-05-03	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2024-06-05	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2024-06-14	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2024-06-20	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602020031989 Country of ref document: DE
2024-07-03	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2024-08-07	U01	Request for unitary effect filed	Effective date: 20240701
2024-08-14	U07	Unitary effect registered	Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI Effective date: 20240710
2024-10-10	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240605
2024-10-11	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240906
2024-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240905 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240605 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240906 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240905
2024-11-13	U20	Renewal fee for the european patent with unitary effect paid	Year of fee payment: 5 Effective date: 20241009
2025-01-16	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240605
2025-01-17	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2994099 Country of ref document: ES Kind code of ref document: T3 Effective date: 20250117
2025-01-23	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241005
2025-01-24	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240605
2025-01-27	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240605 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240605
2025-01-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240605
2025-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240605 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240605 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240605 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240605 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20241005 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240605
2025-02-28	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2025-03-19	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240605
2025-03-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240605
2025-04-11	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2025-04-11	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2025-04-24	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240731
2025-05-14	26N	No opposition filed	Effective date: 20250306
2025-05-28	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20240905
2025-07-10	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240905
2025-07-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240709
2025-09-03	U20	Renewal fee for the european patent with unitary effect paid	Year of fee payment: 6 Effective date: 20250728
2025-10-09	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: ES Payment date: 20250801 Year of fee payment: 6
2025-11-10	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20200709
2026-03-06	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20200709

Publication	Publication Date	Title
IL292753A (en)	2022-07-01	Compounds
IL283692A (en)	2021-07-29	Novel composition
EP3994692C0 (fr)	2024-09-11	Cellule binaire de calcul en mémoire
DK4083038T3 (da)	2024-12-09	Pyridazinylthiazolcarboxamidforbindelse
IL286833A (en)	2021-10-31	Compositions containing brazzein
LT3810602T (lt)	2024-01-25	Junginiai
EP3930851A4 (fr)	2023-03-29	Polythérapies
EP3919491C0 (fr)	2025-05-28	Inhibiteur d'akt
IL288173A (en)	2022-01-01	Sonosensitization
EP3967649C0 (fr)	2025-11-12	Nanoparticule lipidique
DK3737677T3 (da)	2022-01-10	Tetrahydroisoquinolinforbindelser
EP3742771C0 (fr)	2024-06-26	Notification m2m sm-sr à sm-dp
HUE065134T2 (hu)	2024-05-28	Vegyületek
DK3808747T3 (da)	2025-02-03	Imidazopyridinon-forbindelse
EP3912517C0 (fr)	2024-08-07	Cadre
LT3867247T (lt)	2024-11-11	Naujieji junginiai
EP3997086C0 (fr)	2024-06-05	Composés de tétrahydroisoquinoline
EP3973348A4 (fr)	2023-02-15	Visiocasques
EP3957391C0 (fr)	2025-01-29	Agitateur
EP3975220A4 (fr)	2022-08-17	Panneau d'affichage
EP3965638C0 (fr)	2024-02-28	Spéculum vaginal
EP3962498A4 (fr)	2023-05-31	Polythérapies
EP3902806C0 (fr)	2026-01-07	Composés de thiénopyridinone
DK3738452T3 (da)	2022-04-19	Fordamper
EP3682831C0 (fr)	2024-05-08	Applicateur cryogénique